RIO DE JANEIRO, BRAZIL - The American company Novavax announced on Tuesday, August 4th, that two studies of its vaccine against the novel coronavirus showed promising preliminary results.
One of them, part of phase 1 of the human trials, showed that 56 volunteers who were administered two doses of the vaccine produced a high level of antibodies against the virus with no serious side effects.
The second, conducted on animals, showed that the immunizing agent was able to prevent infection in monkeys.
Though little known, the Maryland-based company in the United States received US$1.6 billion (R$8 billion . . .